arena pharmaceuticals inc
(ARNA:NASDAQ GS)
As of 8:10 PM 05/23/13 All times are local (Market data is delayed by at least 15 minutes).
Financial Statements for arena pharmaceuticals inc (ARNA)
Year over year, Arena Pharmaceuticals, Inc. has been able to grow revenues from $12.7M USD to $27.6M USD. Most impressively, the company has been able to reduce the percentage of sales devoted to selling, general and administrative costs from 190.64% to 95.07%. This was a driver that led to an improvement in the bottom line from a loss of $109.2M USD to a smaller loss of $85.5M USD.
| Currency in Millions of US Dollars | As of: | Dec 31 2009 | Dec 31 2010 Restated | Dec 31 2011 Reclassified | Dec 31 2012 | 4 Year Trend |
| Revenues | 10.4 | 16.6 | 12.7 | 27.6 |  | |
| TOTAL REVENUES | 10.4 | 16.6 | 12.7 | 27.6 | | |
| Cost of Goods Sold | 6.5 | 18.0 | 14.7 | 11.6 | | |
| GROSS PROFIT | 3.9 | -1.4 | -2.0 | 16.0 | | |
| Selling General & Admin Expenses, Total | 25.2 | 27.9 | 24.2 | 26.2 | | |
| R&D Expenses | 110.2 | 64.9 | 52.1 | 46.2 | | |
| Depreciation & Amortization, Total | 3.5 | 2.2 | 1.0 | 0.7 | | |
| OTHER OPERATING EXPENSES, TOTAL | 138.9 | 95.0 | 77.4 | 73.1 | | |
| OPERATING INCOME | -135.1 | -96.4 | -79.3 | -57.1 | | |
| Interest Expense | -18.7 | -21.7 | -14.3 | -9.1 | | |
| Interest and Investment Income | 0.7 | 0.5 | 0.1 | 0.1 | | |
| Other Non-Operating Expenses, Total | -0.4 | 5.4 | 0.2 | -13.0 | | |
| Other Non-Operating Income (Expenses) | -0.4 | 5.4 | 0.2 | -13.0 | | |
| Merger & Restructuring Charges | -3.3 | -- | -3.5 | -- | | |
| Gain (Loss) on Sale of Investments | -- | -- | -2.0 | -- | | |
| Other Unusual Items, Total | 2.9 | -12.4 | -10.5 | -6.3 | | |
| EBT, INCLUDING UNUSUAL ITEMS | -153.9 | -124.5 | -109.2 | -85.5 | | |
| Income Tax Expense | -0.7 | -- | -- | -- | | |
| Earnings from Continuing Operations | -153.2 | -124.5 | -109.2 | -85.5 | | |
| NET INCOME | -153.2 | -124.5 | -109.2 | -85.5 | | |
| NET INCOME TO COMMON INCLUDING EXTRA ITEMS | -153.2 | -124.5 | -111.5 | -88.3 | | |
| NET INCOME TO COMMON EXCLUDING EXTRA ITEMS | -153.2 | -124.5 | -111.5 | -88.3 | | |
| Recently Viewed | |||
| ARNA:US | $8.06 USD | +0.14 |  |
| Company | Last | Change |
| Cell Therapeutics Inc | $1.22 USD | -0.07 |
| GlaxoSmithKline Consumer Healthcare Ltd | 4,856 INR | -96.95 |
| GlaxoSmithKline PLC | 1,731 GBp | -11.00 |
| Roche Holding AG | SFr.252.50 CHF | +1.80 |
| Vivus Inc | $14.50 USD | +0.98 |
| View Industry Companies | ||
Industry Analysis
ARNA
Industry Average
| Valuation | ARNA | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 62.6x |
|
| Price/Book | 21.6x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 55.1x |
|
